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A novel fluorescent labeling method for alprenolol was developed based on 
Mizoroki-Heck coupling reaction.  We designed and synthesized fluorescent aryl 
iodide, 4-(4,5-diphenyl-1H-imidazol-2-yl)iodobenzene (DIBI) as a labeling reagent.  
DIBI has a lophine skeleton carrying an iodide atom acting as fluorophore and 
reactive center, respectively.  In order to evaluate the usefulness of DIBI, a high-
performance liquid chromatography (HPLC) with fluorescence detection method was 
developed for the determination of alprenolol as a model compound of terminal 
double bond.  The fluorescent labeling of alprenolol with DIBI was achieved in the 
presence of palladium acetate as a catalyst, and the labeled alprenolol was detected 
fluorometrically.   In addition, it was found that the fluorescence of DIBI derivative 
increased and red shifted when compared that of DIBI.  Furthermore, the proposed 
method could be applied to determine the alprenolol concentration in rat plasma after 
administration of alprenolol without interferences from biological components.    The 
detection limit (S/N=3) for alprenolol in rat plasma was 0.74 ng/mL (30 fmol on 
column).   
 
 
Keywords: Fluorescent labeling, Terminal double bond, Fluorescent aryl iodide, 





The fluorescent labeling reagent is useful for sensitive fluorescence analysis of 
non- or weakly fluorescent analytes in combination with appropriate separation 
techniques such as high-performance liquid chromatography (HPLC) and capillary 
electrophoresis (CE).   Many fluorescent labeling reagents have been developed for a 
various functional groups such as amine, phenol, thiol, aldehyde and carbonyl groups 
[1-4].  Although the fluorescent labeling reagents are frequently applied to the drug 
analysis in biological fluids, there are drawbacks as follows: (1) fluorescent labeling 
technique cannot be applied to compounds which do not possess derivatizable 
functional groups,  (2) fluorescent labeling reagent reacts with co-existing biological 
substances and the resultant products can interfere with the detection of target analyte.  
Recently, we developed a novel fluorescent labeling technique based on Suzuki 
coupling reaction which is a palladium-catalyzed cross-coupling reaction between 
aryl halides and aryl boronic acids [5].  We designed and synthesized fluorescent aryl 
boronic acid, 4-(4,5-diphenyl-1H-imidazol-2-yl)phenylboronic acid (DPA, a lophine 
derivative) as a fluorescent labeling reagent for aryl halides [5, 6].    The Suzuki 
coupling reaction with DPA introduces fluorophore to the target analytes having an 
aryl halide in their structures, even in the absence of the derivatizable functional 
groups by a conventional fluorescent labeling reagent.  Furthermore, DPA-labeled 
compounds can be detected clearly without interference on the chromatogram because 
DPA does not react with most of biological compounds.  The practicability of the 
labeling procedure by DPA was confirmed in the successful analysis of the aryl halide 
drugs including clofibrate [5], haloperidol [7] and hydroxyzine [8] in biological fluids.   
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In addition to Suzuki coupling reaction, several types of palladium coupling 
reaction have been developed.  Among them, the Mizoroki-Heck coupling reaction, 
one of such coupling reaction, is a palladium-catalyzed carbon-carbon bond formation 
between aryl halides and terminal double bonds [9-11].  We considered that 
Mizoroki-Heck reaction would become a new type of labeling reaction against 
terminal double bond by using fluorescent aryl halide as a labeling reagent.  The aim 
of the present work is the establishment of a novel fluorescent labeling technique for 
terminal double bond based on Mizoroki-Heck coupling reaction in order to expand 
the application range of palladium coupling reaction in the field of analytical 
chemistry.  For this purpose, we synthesized fluorescent aryl iodide, 4-(4,5-diphenyl-
1H-imidazol-2-yl)iodobenzene (DIBI) as a specific fluorescent labeling reagent for 
terminal double bond (Fig. 1).  DIBI has a lophine skeleton carrying an iodide atom 
acting as fluorophore and reactive center, respectively.  In this study, we applied DIBI 
to the development of determination method for alprenolol as a model compound of 
double bond.  Alprenolol is a -blocker that has a terminal double bond moiety and is 
used for treatment of cardiovascular diseases.  Since the serial side effects of 
alprenolol, such as heart failure were reported, the sensitive and selective 
determination method for alprenolol should be useful to guide dosing of alprenolol 
[12, 13].  We confirmed that alprenolol could be sensitively determined after its 
derivatization with DIBI (Fig. 1).  Furthermore, the developed method was 
successfully applied to the determination of alprenolol in rat plasma without any 






2.1 Material and reagents 
 
 Alprenolol was obtained from Sigma (St. Louis, MO, USA).  Palladium (II) 
acetate (Pd(OAc)2), acetic acid, N,N-dimethylacetamide (DMAc) and chloroform 
were purchased from Nacalai Tesque (Osaka, Japan).   Acetonitrile (HPLC grade) was 
from Kanto Chemical (Tokyo, Japan).  Triethylamine (TEA), ammonium acetate, 
iodobenzene and sodium hydroxide (NaOH) were from Wako (Tokyo, Japan).  Benzil, 
p-iodobenzaldehyde and dimethyl sulfate were purchased from Tokyo Chemical 
Industries (Tokyo, Japan).  DIBI, DIB-alprenolol and N,O-dimethylated alprenolol as 
an internal standard (IS) were synthesized as described in later sections.  Water was 
distilled and passed through a Pure Line WL21P system (Yamato, Tokyo, Japan).  All 
other chemicals were the highest purity and quality available.  Stock solutions of 
alprenolol, IS and DIBI were prepared in DMAc and stored at 4 ºC.  Pd(OAc)2 and 




The HPLC system consisted of a Shimadzu LC-9A pump (Kyoto, Japan), a 
Shimadzu RF-10AxL fluorescence detector, a Rheodyne 7125 injector with a 20-µL 
loop (Cotati, CA, USA), and a Tosoh FBR-1 recorder (Tokyo, Japan).   Fluorescence 
spectra were measured with a Hitachi 650-10S fluorescence spectrophotometer 
(Tokyo, Japan).  1H-NMR spectral data were obtained on a Varian Unity plus 
spectrometer (Palo Alto, CA, USA).  Mass spectral data were obtained on a JEOL 
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JMS-700N spectrometer (Tokyo, Japan).  Elemental analyses were performed on a 
Perkin Elmer 2400II (Norwalk, CT, USA).  Melting points were measured with a 
Yanagimoto MP-53 melting point apparatus (Tokyo, Japan). 
 
2.3 Synthesis of DIBI 
 
 DIBI was synthesized according to the previous papers [14,15].   p-
Iodobenzaldehyde (110 mg, 0.5 mmol), ammonium acetate (97 mg, 1.25 mmol) and 
benzil (53 mg, 0.25 mmol) were dissolved in 2.5 mL of acetic acid.  This mixture was 
heated at 100 °C for 8 h.  After cooling to room temperature, the mixture was poured 
into cold water. The resultant precipitate was recrystallized from methanol to give 
colorless crystals; yield: 102 mg, 96%, mp: 260 °C.  Elemental analysis; Calculated 
for C21H15N2I: C, 59.72%; H, 3.58%, N, 6.63%, found: C, 59.94%, H, 3.34%, N, 
6.51%. High resolution EI-MS (m/z) found: 422.0291, calculated: 422.0279 [M+].  
1H-NMR (500 MHz, DMSO-d6): ppm = 12.75 (s, 1 H, NH), 7.89 (d, J = 8.5 Hz, 2 
H, 2-phenyl), 7.85 (d, J = 8.5 Hz, 2 H, 2-phenyl), 7.53-7.23 (m, 10 H, 4 and 5-phenyl). 
 
2.4 Preparation of authentic DIB-alprenolol 
 
 Alprenolol (143 mg, 0.5 mmol) and DIBI (106 mg, 0.25 mmol) were 
dissolved in DMAc (7 mL). To this solution, Pd(OAc)2 (1.7 mg, 7.5 µmol) and TEA 
(70 µL, 0.5 mmol) were added and then the solution was purged with N2 (5.0 
mL/min) for 5 min.  After heating at 100 °C for 3 h, the solution was filtered and 
poured into cold water.  To this solution, 1 M NaOH aqueous solution was added until 
precipitate was obtained.  The resulting precipitate was filtered, and a portion of the 
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crude product was purified by chromatography on silica gel using ethyl acetate 
containing 4% TEA to give DIB-alprenolol as yellow crystals; yield: 20 mg, 15%, 
mp: 87 °C.  Elemental analysis: Calculated for C36H37N3O2•1.2H2O, calculated: C, 
76.49%; H, 7.02%; N, 7.43%, found: C, 76.23%; H, 7.12%; N, 7.48%.  High 
resolution FAB-MS (m/z) found: 544.2971, calculated: 544.2964 [M+H]+.  1H-NMR 
(500 MHz, CD3OD): ppm = 7.92-7.19 (m, 18 H, phenyl), 6.84 (d, J = 16 Hz, 1 H, -
Ph-CH=CH-CH2-), 6.42 (m, 1 H, -Ph-CH=CH-CH2-), 4.15 (m, 1 H, -CH2-CH(OH)-
CH2-), 4.02 (m, 2 H, -O-CH2-CH(OH)-), 3.60 (m, 2 H, =CH-CH2-Ph-), 2.98 (m, 2H, -
CH(OH)-CH2-NH-), 2.84 (m, 1H, -NH-CH(CH3)2), 1.12 (m, 6H, -CH(CH3)2). 
 
2.5 Preparation of N,O-dimehtylated alprenolol 
 
 Alprenolol (206 mg, 0.72 mmol) and dimethyl sulfate (288 µL, 3.04 mmol) 
were dissolved in 2M NaOHaq (0.9 mL).  After the reaction at 4 °C for 2 h, the 
mixture was purified by preparative HPLC using Tosoh TSK-GEL ODS-80TM (300 
mm x 7.8 mm i.d., 10 µm) eluted with a mixture of acetonitrile and water (=50:50, 
v/v) containing 0.1% trifluoroacetic acid at a flow rate of 1.0 mL/min.    N,O-
Dimethylated alprenolol was extracted from the eluted fraction with dichloromethane, 
and then the organic phase was evaporated to give N,O-dimethylated alprenolol as a 
colorless oil; yield: 135 mg, 67%.  Elemental analysis: Calculated for 
C17H27N1O2•0.85CH2Cl2, calculated: C, 61.33%; H, 8.27%; N, 4.01%, found: C, 
61.39%; H, 8.09%; N, 3.63%.  FAB-MS (m/z) found: 263, calculated: 263 [M-CH3]
+.  
1H-NMR (500 MHz, CD3OD): ppm = 7.26-6.90 (m, 4 H, phenyl), 5.94 (m, 1 H, 
CH2=CH-CH2-Ph-), 4.90 (m, 2 H, CH2=CH-CH2-Ph-), 4.76 (m, 1 H, -CH2-
CH(OCH3)-CH2-), 4.02 (m, 2 H, -O-CH2-CH(OCH3)-), 3.82 (m, 2 H, CH2=CH-CH2-
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Ph-), 3.53 (m, 1 H, -N(CH3)-CH(CH3)2), 3.32 (m, 2 H, -CH(OCH3)-CH2-N(CH3)-), 
3.27 (s, 3 H, -CH2-CH(OCH3)-CH2-), 3.24 (s, 3 H, -CH2-N(CH3)-CH2-), 1.43 (dd, J = 
6.3, 16 Hz, 6H, -CH(CH3)2). 
 
2.6 Fluorescent labeling procedure and HPLC conditions 
 
 To the DMAc solution (50 µL) including 4.00-600 ng/mL alprenolol and 150 
ng/mL IS, 7 mM DIBI in DMAc (50 µL), 20 µM Pd(OAc)2 in DMAc (50 µL) and 50 
mM TEA in water (50 µL) were successively added and mixed well.  After purging 
with N2 (5.0 mL/s) for 15 s, the reaction mixture was heated at 100 ºC for 15 min.  
After filtration through a membrane filter (0.45 µm, HLC-DISK 3, Kanto chemical), a 
20 µL of aliquot was injected into HPLC system. 
 Chromatographic separation was performed on a Merck Lichrosorb Si60 (250 
mm x 4 mm i.d., 5 µm) by using an isocratic elution with a mixture of acetonitrile and 
water (=90:10, v/v) containing 0.02% TEA and 0.02% acetic acid at a flow rate of 1.0 
mL/min.  The excitation and emission wavelengths were set at 330 nm and 420 nm, 
respectively. 
 
2.7 Assay procedure for alprenolol in rat plasma 
 
Wistar male rat (274 g, Tagawa experimental animals, Nagasaki, Japan) was 
used for experiment.  Rat was anesthetized with ethyl carbamate (1.5 µg/kg, i.p.).  
Alprenolol was administered (i.a.) via arteria femoralis at a dose of 5 mg/kg.  Blood 
samples were collected through indwelling arterial catheters, transferred to EDTA 
tubes and centrifuged at 5000 g for 10 min, then the plasma was separated and stored 
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at -80 °C in the dark until analysis.  The experiment was performed with an approval 
of  the Nagasaki University Animal Care and Use Committee. 
One-hundred micro liters of plasma were spiked with 10 µL of 3 µg/mL IS in 
DMAc and then 400 µL of 0.1 M NaOH aqueous solution was added.  To this 
solution, 2 mL of chloroform was added and vortexed for 60 s followed by 
centrifugation at 5000 g for 10 min.  This extraction was repeated again.  The organic 
layer was transferred to a screw-capped amber-colored reaction vial and evaporated in 
a centrifugal evaporator for 10 min. The residue was reconstituted in 50 µL of DMAc 




3. Results and Discussion 
 
3.1 Fluorescence characteristics of DIBI and DIB-alprenolol 
 
 We selected aryl iodide as a reactive group for labeling because it was known 
that the reactivity order of aryl halides in Mizoroki-Heck reactions is usually aryl 
iodide > aryl bromide  > aryl chloride [16].  DIBI could be obtained by the relatively 
simple reaction as described in section 2.2.   Figure 2 shows the fluorescence spectra 
of the DIBI and authentic DIB-alprenolol.  The fluorescence intensity of DIB-
alprenolol was approximately 4 times higher than that of DIBI.  The increase in 
fluorescence might be attributed to the elimination of iodine group during the reaction, 
which acts as a quencher of fluorescence.  Additionally, the maximum emission 
wavelength of DIB-alprenolol (415 nm) was significantly longer than that of DIBI 
(390 nm).  The extension of the conjugation structure might cause the red shift of the 
fluorescence emission wavelength.  The changes of fluorescence characteristic of 
DIBI along with labeling reaction should be advantageous because the reagent blank 
peaks derived from excess DIBI can be reduced on the chromatogram.   
 
3.2. Optimization of labeling reaction conditions 
 
Figure 3 (A) and (B) shows the typical chromatograms obtained from reagent 
blank and the reaction mixture of alprenolol and IS with DIBI, respectively.  The 
alprenolol and IS were successfully labeled with DIBI, and were detected at 17 and 25 
min on the chromatogram, respectively.   
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In order to obtain higher reactivity, the labeling reaction conditions were 
optimized using a standard solution of alprenolol and IS.  The effect of organic 
solvent for alprenolol and DIBI was examined with DMAc, dimethyl formamide, N-
methylpyrolidone, dioxane, methanol and acetonitrile.  Among these solvents, the 
optimal result was obtained with DMAc and it was selected for subsequent work.   
The concentration of DIBI was investigated over a range 0.5-10 mM, and the 
maximum peak height of alprenolol was obtained at a concentration of 7 mM (Fig. 4).  
Under the optimized condition, the molar ratio of DIBI to alprenolol was 
approximately 14,000.  The effect of base was investigated using TEA, sodium 
carbonate, tripotassium phosphate, potassium fluoride and dipotassium carbonate.  
Among the examined bases, the optimal result was obtained with TEA.  Then, the 
concentration of TEA was studied over a range of 20-60 mM and 50 mM of TEA was 
selected because it gave maximum peak heights.  The effect of Pd(OAc) 2 
concentration was investigated over a range of 5-40 µM, and the maximum peak 
height of alprenolol was observed at 20 µM; 20 µM of Pd(OAc) 2 was selected.  The 
reaction temperature was selected at 100 ºC because the peak heights increased with 
increasing the temperature.  The effect of reaction time was investigated at 100 ºC 
until 30 min.  Since the maximum peak heights were achieved by heating for more 
than 10 min, 15 min was selected.  Under the optimized conditions, the reaction yields 
for alprenolol was calculated by comparing the peak heights of the reaction products 
and authentic DIB-alprenolol.  The reaction yields was 97%, suggesting that the 




3.3. Optimization of extraction conditions 
 
The extraction conditions of alprenolol from rat plasma were investigated.  For 
the effective extraction of alprenolol and IS from plasma, liquid-liquid extraction was 
investigated as a sample treatment by using 100-µL plasma spiked with alprenolol.  
To choose the extraction solvent, chloroform, n-hexane and diethyl ether were 
compared and the maximum recovery was obtained with chloroform; chloroform was 
employed.  Both the volume of extraction solvent and the number of extraction were 
studied using 1.0-3.0 mL of chloroform with one or twice extraction.  The optimal 
volume and number were 2.0 mL and twice extraction, respectively.  NaOH was 
added to plasma in order to inhibit the dissociation of amino group of alprenolol.  The 
effect of NaOH concentration was examined over the range of 0.01-0.5 M.  Maximal 
and constant recoveries were obtained more than 0.05 M of NaOH; 0.1 M NaOH was 
selected.  After the optimization of the extraction conditions, the recoveries of 
alprenolol and IS were 89 and 75%, respectively. 
 
3.4 Calibration curve, detection limit and repeatability 
 
A calibration curve was prepared by spiking plasma with known amount of 
alprenolol.  A linear relationship (r=0.999) was obtained between peak height ratio of 
alprenolol to IS and alprenolol concentration over the range from 2.00 to 300 ng/mL.  
The slope and intercept of regression equation (mean ± standard error, n = 3) were 
0.031 ± 0.006 and −0.059 ± 0.017, respectively.  The detection limit of alprenolol in 
rat plasma was 0.74 ng/mL (30 fmol on column) at a signal-to-noise ratio (S/N) of 3.  
The sensitivity of the proposed method was approximately 600, 60 and 14 times 
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higher than that of HPLC with amperometric detection [17], ELISA [18] and HPLC 
with atmospheric pressure chemical ionization mass spectrometry [19].  Although the 
sensitivity of the proposed method was comparable with that of HPLC with tandem 
mass spectrometry [20], the proposed method does not require expensive and 
elaborate instruments.  Accuracy and precision of the proposed method were 
examined using three levels (2.0, 15 and 60 ng/mL) of alprenolol in rat plasma (Table 
1).  As shown in Table 1, the within- and between-day accuracy of alprenolol ranged 
from 90.2% to 105.0% with precision values less than 9.5%.  These results indicated 
that the proposed method showed sufficient accuracy and precision.   
 
3.5 Determination of alprenolol in rat plasma after administration 
 
The alprenolol concentration in rat plasma after a single dose of alprenolol 
was determined by the proposed method.  Typical chromatograms of rat plasma in the 
absence of alprenolol and IS, rat plasma collected after 60 and 420 min after the i.a. 
administration of alprenolol (5 mg/kg) are shown in Fig. 5 (A), (B) and (C), 
respectively.  The peak of alprenolol could be detected clearly and there were no 
interfering peaks derived from plasma components because DIBI could react 
specifically with terminal double bond and did not react with most of biological 
compounds.    As shown in Fig. 5 (B) and (C), the plasma concentration of alprenolol 
decreased with time after administration.  This decrease could be attributed to the 
disappearance of alprenolol from the blood by metabolism and excretion.  Therefore, 
the proposed method should be useful to investigate the pharmacokinetic parameters 
of terminal double bond drugs.  Also, it has been reported that (S)-enantiomer of the 
-blocker showed stronger pharmacological activity than (R)-enantiomer [21].  
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Therefore, selective determination of individual enantiomers of alprenolol should be 
useful to properly assess their own pharmacological effects.  The application of the 
proposed labeling reaction to the separation by HPLC equipped with a chiral 
stationary phase column should allow highly sensitive and enantioselective 






 In this study, we employed fluorescent aryl iodide, DIBI as a specific 
fluorescent labeling reagent for alprenolol.  DIBI reacted with terminal double bond 
of alprenolol based on Mizoroki-Heck coupling reaction.  By using DIBI, we 
developed a sensitive and selective HPLC determination method for alprenolol.    The 
fluorescent labeled alprenolol was clearly detected on the chromatogram even in the 
presence of biological components.  The proposed method could be applied to the 
determination of alprenolol concentration in rat plasma after administration of 
alprenolol.  Since the proposed labeling technique is specific for terminal double bond 
and allows sensitive detection, DIBI should be useful for real sample analysis of 
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Figure captions  
 
Fig. 1. Fluorescence labeling reaction of alprenolol with DIBI based on Mizoroki-
Heck coupling reaction. 
 
Fig. 2.  Fluorescence spectra of 2.5 µM DIBI and 2.5 µM DIB-alprenolol.  Excitation 
spectra of (A) DIBI with emission at 390 nm and (B) DIB-alprenolol with 
emission at 405 nm.  Emission spectra of (C) DIBI with excitation at 315 nm 
and (D) DIB-alprenolol with excitation at 325 nm. 
 
Fig. 3  Chromatograms of (A) reagent blank and (B) standard solution of alprenolol 
and IS.  The concentrations of alprenolol and IS were 120 and 150 ng/ml, 
respectively.  
 
Fig. 4  Effect of DIBI concentration on the peak heights of alprenolol and IS. The 
concentrations of alprenolol and IS were 120 and 150 ng/ml, respectively. 
 
Fig. 5  Chromatograms of (A) blank rat plasma and rat plasma after (B) 60 min and 












Fig. 1  Fluorescence labeling reaction of alprenolol with DIBI based on






Fig. 2. Fluorescence spectra of 2.5 µM DIBI and 2.5 µM DIB-alprenolol.  
Excitation spectra of (A) DIBI with emission at 390 nm and (B) DIB-
alprenolol with emission at 415 nm.  Emission spectra of (C) DIBI with 
excitation at 315 nm and (D) DIB-alprenolol with excitation at 335 nm. 
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Fig. 3 Chromatograms of (A) reagent blank and (B) standard solution of 
alprenolol and IS.  The concentrations of alprenolol and IS were 120 and 
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Fig. 4 Effect of DIBI concentration on the peak heights of alprenlol and IS. 





Fig. 5 Chromatograms of (A) blank rat plasma and rat plasma after (B) 60 min 
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Table 1 Within- and between-day accuracy and precision of the proposed 
method for determination of alprenolol in rat plasma. 
 









2 98.8 4.4 90.2 9.5 
15 103.9 4.2 105.0 5.3 
60 95.1 2.7 99.6 3.8 
a Relative standard deviation 
 
